Found: 74
Select item for more details and to access through your institution.
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01155-y
- By:
- Publication type:
- Article
The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 7, p. 1, doi. 10.1007/s00520-024-08663-4
- By:
- Publication type:
- Article
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 9, p. 7469, doi. 10.1007/s00520-022-07173-5
- By:
- Publication type:
- Article
Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 5, p. e43, doi. 10.1111/bjh.18948
- By:
- Publication type:
- Article
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 328, doi. 10.1111/bjh.18216
- By:
- Publication type:
- Article
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 6, p. e63, doi. 10.1111/bjh.17969
- By:
- Publication type:
- Article
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. e33, doi. 10.1111/bjh.17903
- By:
- Publication type:
- Article
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. e21, doi. 10.1111/bjh.17864
- By:
- Publication type:
- Article
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 5, p. 857, doi. 10.1111/bjh.17441
- By:
- Publication type:
- Article
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 4, p. 750, doi. 10.1111/bjh.17377
- By:
- Publication type:
- Article
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. e19, doi. 10.1111/bjh.17391
- By:
- Publication type:
- Article
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. e73, doi. 10.1111/bjh.17248
- By:
- Publication type:
- Article
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 1, p. e14, doi. 10.1111/bjh.17168
- By:
- Publication type:
- Article
A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 5, p. 927, doi. 10.1111/bjh.17076
- By:
- Publication type:
- Article
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. e312, doi. 10.1111/bjh.16889
- By:
- Publication type:
- Article
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e83, doi. 10.1111/bjh.16874
- By:
- Publication type:
- Article
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 643, doi. 10.1111/bjh.16401
- By:
- Publication type:
- Article
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 5, p. 638, doi. 10.1111/bjh.16122
- By:
- Publication type:
- Article
Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 162, doi. 10.1111/bjh.15743
- By:
- Publication type:
- Article
Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 948, doi. 10.1111/bjh.15649
- By:
- Publication type:
- Article
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 573, doi. 10.1111/bjh.15551
- By:
- Publication type:
- Article
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 350, doi. 10.1111/bjh.15487
- By:
- Publication type:
- Article
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 344, doi. 10.1111/bjh.15457
- By:
- Publication type:
- Article
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 6, p. 936, doi. 10.1111/bjh.14897
- By:
- Publication type:
- Article
Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 3, p. 495, doi. 10.1111/bjh.14086
- By:
- Publication type:
- Article
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 6, p. 908, doi. 10.1111/bjh.14547
- By:
- Publication type:
- Article
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 2, p. 222, doi. 10.1111/bjh.14401
- By:
- Publication type:
- Article
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 1, p. 148, doi. 10.1111/bjh.13072
- By:
- Publication type:
- Article
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non- Hodgkin lymphoma pre-clinical models.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 1, p. 135, doi. 10.1111/bjh.12456
- By:
- Publication type:
- Article
Antibody drug conjugates for the treatment of multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, p. S22, doi. 10.1002/ajh.26750
- By:
- Publication type:
- Article
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
- Published in:
- Frontiers in Medicine, 2023, p. 1, doi. 10.3389/fmed.2023.1271657
- By:
- Publication type:
- Article
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.703233
- By:
- Publication type:
- Article
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. 665, doi. 10.1016/j.clml.2024.05.003
- By:
- Publication type:
- Article
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
- By:
- Publication type:
- Article
P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
- By:
- Publication type:
- Article
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S59, doi. 10.1016/S2152-2650(21)02173-X
- By:
- Publication type:
- Article
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02121-2
- By:
- Publication type:
- Article
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S2, doi. 10.1016/S2152-2650(21)02077-2
- By:
- Publication type:
- Article
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
- By:
- Publication type:
- Article
MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S428, doi. 10.1016/S2152-2650(21)01955-8
- By:
- Publication type:
- Article
MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01944-3
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Poster: MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S255, doi. 10.1016/S2152-2650(21)01598-6
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article
Poster: MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01577-9
- By:
- Publication type:
- Article
Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e309, doi. 10.1016/j.clml.2019.09.508
- By:
- Publication type:
- Article
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e288, doi. 10.1016/j.clml.2019.09.475
- By:
- Publication type:
- Article
Real World Use of Ixazomib With Lenalidomide and Dexamethasone for Patients With Relapsed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e264, doi. 10.1016/j.clml.2019.09.436
- By:
- Publication type:
- Article